Two-Year Safety and Efficacy of Biodegradable Polymer Drug-Eluting Stent Versus Second-Generation Durable Polymer Drug-Eluting Stent in Patients With Acute Myocardial Infarction

Data from the Korea Acute Myocardial Infarction Registry (KAMIR)

Seung Ho Hur, In Cheol Kim, Ki Bum Won, Yun Kyeong Cho, Hyuck Jun Yoon, Chang Wook Nam, Kwon Bae Kim, Min Seok Kim, Jincheol Park, Seung-Woon Rha, Shung Chull Chae, Young Jo Kim, Chong Jin Kim, Myeong Chan Cho, Myung Ho Jeong, Young Keun Ahn, Hyo Soo Kim, Tae Hoon Ahn, Ki Bae Seung, Yangsoo Jang & 5 others Jung Han Yoon, In Whan Seong, Taek Jong Hong, Jang Ho Bae, Seung Jung Park

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Despite improved long-term safety of biodegradable polymer (BP) drug-eluting stents (DES) compared to first-generation durable polymer (DP) DES, data on the safety and efficacy of BP-DES compared with second-generation (2G) DP-DES in patients with acute myocardial infarction (AMI) are limited. Hypothesis: To evaluate the safety and efficacy of BP-DES compared with 2G-DP-DES in the higher stent thrombosis (ST) risk setting of AMI. Methods: A total of 3359 AMI patients who received either BP-DES (n = 261) or 2G-DP-DES (n = 3098) were included from the Korea Acute Myocardial Infarction Registry (KAMIR). Differences in baseline clinical and angiographic characteristics were adjusted using a 1:5 propensity score matching analysis (n = 261 for BP-DES and n = 1305 for 2G-DP-DES). The primary outcome was the incidence of major adverse cardiac events (MACE) including all-cause death, recurrent myocardial infarction (re-MI), and target vessel revascularization (TVR). The rate of definite or probable ST was also investigated. Results: In adjusted analysis, there was no significant difference between the 2 groups in baseline clinical and angiographic characteristics; 2-year MACE (10.7% and 9.9% in the BP-DES group and 2G-DP-DES group, respectively, P = 0.679); ST incidence (0.8% vs 0.9%, respectively, P = 1.0), and rates of all-cause death, re-MI, and TVR. By multivariate analysis, old age, diabetes mellitus, renal dysfunction, and left ventricular dysfunction were the independent predictors of MACE after BP-DES or 2G-DP-DES implantation. Conclusions: BP-DES and 2G-DP-DES appear to have comparable 2-year safety and efficacy for the treatment of AMI. However, longer-term follow-up is needed.

Original languageEnglish
JournalClinical Cardiology
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Drug-Eluting Stents
Korea
Registries
Polymers
Myocardial Infarction
Safety
Stents
Thrombosis
Cause of Death
Propensity Score
Incidence
Left Ventricular Dysfunction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Two-Year Safety and Efficacy of Biodegradable Polymer Drug-Eluting Stent Versus Second-Generation Durable Polymer Drug-Eluting Stent in Patients With Acute Myocardial Infarction : Data from the Korea Acute Myocardial Infarction Registry (KAMIR). / Hur, Seung Ho; Kim, In Cheol; Won, Ki Bum; Cho, Yun Kyeong; Yoon, Hyuck Jun; Nam, Chang Wook; Kim, Kwon Bae; Kim, Min Seok; Park, Jincheol; Rha, Seung-Woon; Chae, Shung Chull; Kim, Young Jo; Kim, Chong Jin; Cho, Myeong Chan; Jeong, Myung Ho; Ahn, Young Keun; Kim, Hyo Soo; Ahn, Tae Hoon; Seung, Ki Bae; Jang, Yangsoo; Yoon, Jung Han; Seong, In Whan; Hong, Taek Jong; Bae, Jang Ho; Park, Seung Jung.

In: Clinical Cardiology, 2016.

Research output: Contribution to journalArticle

Hur, SH, Kim, IC, Won, KB, Cho, YK, Yoon, HJ, Nam, CW, Kim, KB, Kim, MS, Park, J, Rha, S-W, Chae, SC, Kim, YJ, Kim, CJ, Cho, MC, Jeong, MH, Ahn, YK, Kim, HS, Ahn, TH, Seung, KB, Jang, Y, Yoon, JH, Seong, IW, Hong, TJ, Bae, JH & Park, SJ 2016, 'Two-Year Safety and Efficacy of Biodegradable Polymer Drug-Eluting Stent Versus Second-Generation Durable Polymer Drug-Eluting Stent in Patients With Acute Myocardial Infarction: Data from the Korea Acute Myocardial Infarction Registry (KAMIR)', Clinical Cardiology. https://doi.org/10.1002/clc.22525
Hur, Seung Ho ; Kim, In Cheol ; Won, Ki Bum ; Cho, Yun Kyeong ; Yoon, Hyuck Jun ; Nam, Chang Wook ; Kim, Kwon Bae ; Kim, Min Seok ; Park, Jincheol ; Rha, Seung-Woon ; Chae, Shung Chull ; Kim, Young Jo ; Kim, Chong Jin ; Cho, Myeong Chan ; Jeong, Myung Ho ; Ahn, Young Keun ; Kim, Hyo Soo ; Ahn, Tae Hoon ; Seung, Ki Bae ; Jang, Yangsoo ; Yoon, Jung Han ; Seong, In Whan ; Hong, Taek Jong ; Bae, Jang Ho ; Park, Seung Jung. / Two-Year Safety and Efficacy of Biodegradable Polymer Drug-Eluting Stent Versus Second-Generation Durable Polymer Drug-Eluting Stent in Patients With Acute Myocardial Infarction : Data from the Korea Acute Myocardial Infarction Registry (KAMIR). In: Clinical Cardiology. 2016.
@article{729329bfd48841869c0351cb69f58091,
title = "Two-Year Safety and Efficacy of Biodegradable Polymer Drug-Eluting Stent Versus Second-Generation Durable Polymer Drug-Eluting Stent in Patients With Acute Myocardial Infarction: Data from the Korea Acute Myocardial Infarction Registry (KAMIR)",
abstract = "Background: Despite improved long-term safety of biodegradable polymer (BP) drug-eluting stents (DES) compared to first-generation durable polymer (DP) DES, data on the safety and efficacy of BP-DES compared with second-generation (2G) DP-DES in patients with acute myocardial infarction (AMI) are limited. Hypothesis: To evaluate the safety and efficacy of BP-DES compared with 2G-DP-DES in the higher stent thrombosis (ST) risk setting of AMI. Methods: A total of 3359 AMI patients who received either BP-DES (n = 261) or 2G-DP-DES (n = 3098) were included from the Korea Acute Myocardial Infarction Registry (KAMIR). Differences in baseline clinical and angiographic characteristics were adjusted using a 1:5 propensity score matching analysis (n = 261 for BP-DES and n = 1305 for 2G-DP-DES). The primary outcome was the incidence of major adverse cardiac events (MACE) including all-cause death, recurrent myocardial infarction (re-MI), and target vessel revascularization (TVR). The rate of definite or probable ST was also investigated. Results: In adjusted analysis, there was no significant difference between the 2 groups in baseline clinical and angiographic characteristics; 2-year MACE (10.7{\%} and 9.9{\%} in the BP-DES group and 2G-DP-DES group, respectively, P = 0.679); ST incidence (0.8{\%} vs 0.9{\%}, respectively, P = 1.0), and rates of all-cause death, re-MI, and TVR. By multivariate analysis, old age, diabetes mellitus, renal dysfunction, and left ventricular dysfunction were the independent predictors of MACE after BP-DES or 2G-DP-DES implantation. Conclusions: BP-DES and 2G-DP-DES appear to have comparable 2-year safety and efficacy for the treatment of AMI. However, longer-term follow-up is needed.",
author = "Hur, {Seung Ho} and Kim, {In Cheol} and Won, {Ki Bum} and Cho, {Yun Kyeong} and Yoon, {Hyuck Jun} and Nam, {Chang Wook} and Kim, {Kwon Bae} and Kim, {Min Seok} and Jincheol Park and Seung-Woon Rha and Chae, {Shung Chull} and Kim, {Young Jo} and Kim, {Chong Jin} and Cho, {Myeong Chan} and Jeong, {Myung Ho} and Ahn, {Young Keun} and Kim, {Hyo Soo} and Ahn, {Tae Hoon} and Seung, {Ki Bae} and Yangsoo Jang and Yoon, {Jung Han} and Seong, {In Whan} and Hong, {Taek Jong} and Bae, {Jang Ho} and Park, {Seung Jung}",
year = "2016",
doi = "10.1002/clc.22525",
language = "English",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Two-Year Safety and Efficacy of Biodegradable Polymer Drug-Eluting Stent Versus Second-Generation Durable Polymer Drug-Eluting Stent in Patients With Acute Myocardial Infarction

T2 - Data from the Korea Acute Myocardial Infarction Registry (KAMIR)

AU - Hur, Seung Ho

AU - Kim, In Cheol

AU - Won, Ki Bum

AU - Cho, Yun Kyeong

AU - Yoon, Hyuck Jun

AU - Nam, Chang Wook

AU - Kim, Kwon Bae

AU - Kim, Min Seok

AU - Park, Jincheol

AU - Rha, Seung-Woon

AU - Chae, Shung Chull

AU - Kim, Young Jo

AU - Kim, Chong Jin

AU - Cho, Myeong Chan

AU - Jeong, Myung Ho

AU - Ahn, Young Keun

AU - Kim, Hyo Soo

AU - Ahn, Tae Hoon

AU - Seung, Ki Bae

AU - Jang, Yangsoo

AU - Yoon, Jung Han

AU - Seong, In Whan

AU - Hong, Taek Jong

AU - Bae, Jang Ho

AU - Park, Seung Jung

PY - 2016

Y1 - 2016

N2 - Background: Despite improved long-term safety of biodegradable polymer (BP) drug-eluting stents (DES) compared to first-generation durable polymer (DP) DES, data on the safety and efficacy of BP-DES compared with second-generation (2G) DP-DES in patients with acute myocardial infarction (AMI) are limited. Hypothesis: To evaluate the safety and efficacy of BP-DES compared with 2G-DP-DES in the higher stent thrombosis (ST) risk setting of AMI. Methods: A total of 3359 AMI patients who received either BP-DES (n = 261) or 2G-DP-DES (n = 3098) were included from the Korea Acute Myocardial Infarction Registry (KAMIR). Differences in baseline clinical and angiographic characteristics were adjusted using a 1:5 propensity score matching analysis (n = 261 for BP-DES and n = 1305 for 2G-DP-DES). The primary outcome was the incidence of major adverse cardiac events (MACE) including all-cause death, recurrent myocardial infarction (re-MI), and target vessel revascularization (TVR). The rate of definite or probable ST was also investigated. Results: In adjusted analysis, there was no significant difference between the 2 groups in baseline clinical and angiographic characteristics; 2-year MACE (10.7% and 9.9% in the BP-DES group and 2G-DP-DES group, respectively, P = 0.679); ST incidence (0.8% vs 0.9%, respectively, P = 1.0), and rates of all-cause death, re-MI, and TVR. By multivariate analysis, old age, diabetes mellitus, renal dysfunction, and left ventricular dysfunction were the independent predictors of MACE after BP-DES or 2G-DP-DES implantation. Conclusions: BP-DES and 2G-DP-DES appear to have comparable 2-year safety and efficacy for the treatment of AMI. However, longer-term follow-up is needed.

AB - Background: Despite improved long-term safety of biodegradable polymer (BP) drug-eluting stents (DES) compared to first-generation durable polymer (DP) DES, data on the safety and efficacy of BP-DES compared with second-generation (2G) DP-DES in patients with acute myocardial infarction (AMI) are limited. Hypothesis: To evaluate the safety and efficacy of BP-DES compared with 2G-DP-DES in the higher stent thrombosis (ST) risk setting of AMI. Methods: A total of 3359 AMI patients who received either BP-DES (n = 261) or 2G-DP-DES (n = 3098) were included from the Korea Acute Myocardial Infarction Registry (KAMIR). Differences in baseline clinical and angiographic characteristics were adjusted using a 1:5 propensity score matching analysis (n = 261 for BP-DES and n = 1305 for 2G-DP-DES). The primary outcome was the incidence of major adverse cardiac events (MACE) including all-cause death, recurrent myocardial infarction (re-MI), and target vessel revascularization (TVR). The rate of definite or probable ST was also investigated. Results: In adjusted analysis, there was no significant difference between the 2 groups in baseline clinical and angiographic characteristics; 2-year MACE (10.7% and 9.9% in the BP-DES group and 2G-DP-DES group, respectively, P = 0.679); ST incidence (0.8% vs 0.9%, respectively, P = 1.0), and rates of all-cause death, re-MI, and TVR. By multivariate analysis, old age, diabetes mellitus, renal dysfunction, and left ventricular dysfunction were the independent predictors of MACE after BP-DES or 2G-DP-DES implantation. Conclusions: BP-DES and 2G-DP-DES appear to have comparable 2-year safety and efficacy for the treatment of AMI. However, longer-term follow-up is needed.

UR - http://www.scopus.com/inward/record.url?scp=84963579228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963579228&partnerID=8YFLogxK

U2 - 10.1002/clc.22525

DO - 10.1002/clc.22525

M3 - Article

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

ER -